WHAT IS CLAIMED IS:

1. A conjugate of the formula

$$B\text{-}L\text{-}(D)_n$$

or a pharmaceutically acceptable salt thereof, wherein B comprises a urea ~~or thiourea~~ of lysine and an amino acid~~, or one or more carboxylic acid derivatives thereof, including, but not limited to ureas or thioureas of lysine and~~ selected from the group consisting of aspartic acid, ~~or~~ glutamic acid, ~~or~~ and homoglutamic acid, where the urea ~~or thiourea~~ is capable of binding to PSMA, L is a polyvalent linker comprising an aminomethylphenylacetic acid diradical, D is a radical of a therapeutic agent ~~drug~~, and n is ~~an integer selected from~~ 1~~, 2, 3, and 4~~.

~~2. The conjugate of claim 1 wherein L is a polyvalent linker comprising an aminomethylphenylacetic acid diradical, or an aminophenylacetic acid diradical, or both.~~

~~3. A conjugate of the formula~~

$$\text{~~B-L-(D)}_{\text{n}}\text{~~}$$

~~or a pharmaceutically acceptable salt thereof, wherein B is a radical of a PSMA binding ligand, L is a polyvalent linker comprising an aminomethylphenylacetic acid diradical or an aminophenylacetic acid diradical or both, D is a radical of a drug, and n is an integer selected from 1, 2, 3, and 4.~~

~~4. The conjugate of claim 3 wherein B comprises a urea or thiourea of lysine and an amino acid, or one or more carboxylic acid derivatives thereof, including, but not limited to ureas or thioureas of lysine and aspartic acid, or glutamic acid, or homoglutamic acid.~~

~~5~~2. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B comprises a urea ~~or thiourea~~ of lysine and glutamate~~, or one or more carboxylic acid derivatives thereof~~.

~~6~~3. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B is selected from the group consisting of ~~following~~



,


,



and


.

~~7~~4. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B is ~~selected from the following~~



~~8. The conjugate of any one of claims 1 to 4 wherein n is 1 or 2.~~

~~9. The conjugate of any one of claims 1 to 4 wherein n is 1.~~

~~10. The conjugate of any one of claims 1 to 4 wherein at least one drug is an imaging agent.~~

~~11. The conjugate of any one of claims 1 to 4 wherein at least one drug is a diagnostic agent.~~

~~12. The conjugate of any one of claims 1 to 4 wherein at least one drug is a therapeutic agent.~~

~~13~~5. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein at least one drug is a cytotoxic agent.

~~14~~6. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein at least one drug is a tubulysin.

~~15~~7. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein L forms a urea or thiourea with the lysine.

~~16~~8. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein L comprises a cysteine diradical.

~~17~~9. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein L is a releasable linker.

~~18~~10. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein L comprises a disulfide.

~~19~~11. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ where L comprises a diradical of the formula



~~20~~12. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B-L comprises a diradical of the formula



~~21~~13. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B-L comprises a

diradical of the formula



.

~~22~~14. The conjugate of ~~any one of claims~~ claim 1 ~~to 4~~ wherein B-L comprises a diradical of the formula



.

~~23~~15. A conjugate of the formula



or a pharmaceutically acceptable salt thereof, where the conjugate or salt thereof is optionally a hydrate, a solvate, or a co-crystal, or a combination thereof.

~~24~~16. The conjugate of claim ~~23~~ 15 in the form of a pharmaceutically acceptable salt.

~~25~~17. The conjugate of claim ~~23~~ 15 in the form of a hydrate.

~~26~~18. The conjugate of claim ~~23~~ 15 in the form of a pharmaceutically acceptable solvate.

~~27~~19. A pharmaceutical composition comprising one or more of the conjugates of any one of claims 1 ~~to 4~~ or ~~23~~ 15 to ~~26~~18.

~~28~~20. Use of one or more of the conjugates of any one of claims 1 ~~to 4~~ or ~~23~~ 15 to ~~26~~18, or a pharmaceutical composition thereof, in the manufacture of a medicament for treatment of a pathogenic cell population in a host animal ~~treating a disease in a host animal caused by a pathogenic population of cells~~, wherein said cells express ~~expressing~~ PSMA.

~~29~~21. The use of claim ~~28~~ 20 wherein the cells are prostate cancer cells.